FreeCME








Decompensated Cirrhosis

Resources for Diagnosis and Management of Clinical Manifestations and Comorbidities

This resource center is supported by an educational grant from Mallinckrodt Pharmaceuticals.

This resource center is designed to give physicians and other health care providers a comprehensive overview of decompensated cirrhosis so that they will better understand how to manage the clinical manifestations and comorbidities of this condition.

Approximately 4.5 million adults in the United States are living with chronic liver disease, representing 1.8% of the population. Cirrhosis is a result of longstanding fibrosis and can result in various negative sequelae, including gastrointestinal hemorrhage, hepatic encephalopathy, ascites, renal failure, and hepatocellular carcinoma. Hepatorenal syndrome (HRS) is a unique form of acute kidney injury (AKI) that develops as an end-stage complication of cirrhosis. The prognosis of HRS-AKI is poor and associated with high mortality, increased lengths of hospital stay, and higher costs of hospitalizations compared with cirrhosis without HRS. Esophageal variceal rupture is the most common fatal complication of cirrhosis; the severity of liver disease correlates with the presence of varices and risk of bleeding. Ascites is the most common complication related to cirrhosis and is associated with increased morbidity and mortality. Refractory ascites occurs in approximately 5% to 10% of all patients with cirrhosis and ascites and is associated with survival of only 50% at 6 months.


Activity Curriculum

Clinical Consultations™: Facilitating Optimal Treatment Outcomes and Multidisciplinary Care in Hepatorenal Syndrome- Acute Kidney Injury (HRS-AKI)

This video-based program utilizes a case-based approach and features two experts discussing the treatment and management of HRS-AKI. In this activity, the faculty focus on the current and emerging therapeutic strategies for the diagnosis and management of HRS-AKI and review investigational therapies.


Advances In™ Cirrhosis: Reframing the Management of Hepatorenal Syndrome-Acute Kidney Injury: A Review of Current Strategies

In this program, Dr Elizabeth Verna and Dr Lisa B. VanWagner outline strategies for diagnosing and treating HRS-AKI patients and take an objective look at pharmacologic treatment, updated pathophysiology, and realistic goals of HRS-AKI treatment with a focus on slowing the progression of disease and consideration of treatment complications.


Burst Expert Illustrations & Commentaries™: Management Strategies for Refractory Ascites

Cirrhosis is a result of longstanding fibrosis and can result in various negative sequelae including ascites. Ascites is the most common complication related to cirrhosis and is associated with increased morbidity and mortality. This multi-media online educational activity is designed to provide expert commentary on the pathophysiology and treatment of refractory ascites.


Burst Expert Illustrations & Commentaries™: Current Treatments for Esophageal Variceal Hemorrhage

Cirrhosis is a result of longstanding fibrosis and can result in various negative sequelae including gastrointestinal hemorrhage, particularly from esophageal varices. This multi-media online educational activity is designed to provide expert commentary on the pathophysiology and treatment of refractory ascites.


Release Date: June 20, 2022

Expiration Date: June 20, 2023

Est. Activity Time: 180 minutes total for all 4 activities

Acknowledgment of Commercial Support

This resource center is supported by an educational grant from Mallinckrodt Pharmaceuticals. 

Faculty, Staff, and Planners’ Disclosures 

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.  

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. 

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.